Letter received from National Medical Products Administration (NMPA) of China regarding Adagloxad Simolenin (OBI-822) Phase III clinical study to be resubmitted after supplementation
Date of occurrence of the event: May 06, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Supplementary announcement for the company to issue ordinary shares through rights offering
Date of the resolution by the board of directors or decision by the Company: Apr 18, 2019 Number of shares issued: 15,000,000 shares Par Value per share: NTD 10 Total …
Supplementary announcement for 2019 Annual General Meeting
Date of the board of directors resolution: Apr 19, 2019 Date for convening the shareholders’ meeting: Jun 27, 2019 Location for convening the shareholders’ meeting: Masterlink Securities Education and Training …
Announcement for the company to issue ordinary shares through rights offering and bank designated for collection and deposition
Date of the resolution by the board of directors or decision by the Company: Apr 18, 2019 Number of shares issued: 15,000,000 shares Par Value per share: NTD 10 Total …
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation
Date of occurrence of the event: Apr 12, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
Announcement for the company to issue ordinary shares through rights offering
Date of the resolution by the board of directors or decision by the Company: Apr 09, 2019 Number of shares issued: 15,000,000 shares Par Value per share: NTD 10 Total …
OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999
Poster Presentations to highlight on mechanism of action, anti-tumor efficacy and pharmacokinetics profile for OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC) TAIPEI, Taiwan, March 28, 2019/OBI Pharma, Inc. …
Announcement of capital change registration for the treasury share retirement
Date of the Competent Authority’s approval of the capital reduction: Mar 26, 2019 Date of completion of capital amendment registration: Mar 26, 2019 Effect on the company financial report (including …
The board of directors have resolved not to distribute dividends for 2018
Date of the board of directors resolution: Mar 8, 2019 Appropriations of earnings in cash dividends to shareholders (NT$ per share): 0 Cash dividends distributed from legal reserve and capital …
The Board of Directors resolved to hold 2019 Annual General Meeting
Date of the board of directors resolution: Mar 8, 2019 Date for convening the shareholders’ meeting: Jun 27, 2019 Location for convening the shareholders’ meeting: Masterlink Securities Education and Training …